Article

Study: moxifloxacin yields higher peak levels than gatifloxacin

Fort Lauderdale, FL-In a comparison of penetration of moxifloxacin HCl ophthalmic solution 0.5% (Vigamox, Alcon Laboratories) and gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) in a human cornea transplant model, mean peak levels of moxifloxacin were higher than those of gatifloxacin in corneal tissue and the aqueous humor, said Edward Holland, MD.

"Moxifloxacin had superior penetration over gatifloxacin," said Dr. Holland, director, Cornea Services, Cincinnati Eye Institute, and professor of ophthalmology, University of Cincinnati, Cincinnati, OH. "We found a three-fold greater level of moxifloxacin (48.5 μg/g) in the corneal stroma and anterior chamber when compared with gatifloxacin (15.7 μg/g). If you looked at the epithelium and endothelium, it was seven-fold and 10-fold higher."

Levels of moxifloxacin and gatifloxacin in the epithelium were 81.2 μg/g and 12.3 μg/g, respectively. In the endothelium, the respective levels were 76.1 μg/g and 7.3 μg/g. The mean peak level of moxifloxacin in the aqueous humor was also approximately three-fold higher than the level of gatifloxacin.

After aqueous humor sampling and excision of the corneal button, the samples were placed on dry ice and shipped for analysis. The corneas were dissected into epithelium, stroma, and endothelium and assayed using a validated simultaneous HPLC-fluorescence method.

The study also shows that high levels of penetration can be achieved with one drop of a fluoroquinolone antibiotic, Dr. Holland said.

"These are further data supporting why you can consider changing your preoperative regimen to administer the antibiotic the day of surgery," he said. "With preoperative dosing of just one drop, you can achieve very high levels of moxifloxacin in the cornea and the anterior chamber. It well exceeds the MIC 90s for all the major pathogens that we're most concerned about for endophthalmitis and keratitis."

The data were presented in a poster at the annual meeting of the Association for Research in Vision and Ophthalmology.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.